Target Oncogenic Receptors in Tumours, A Hot Topics Today

Abstract

Since the discovery of oncogenic receptor by George Zhu from oncogenic pml/RARa fusion in the origin of a specific APL and androgen/oncogenic androgen receptor signaling in hormonal tumorigenesis in 1989s, many studies are dedicated on their clinical targeting therapy. At present, thousands of publications and over 100 global journals are focused on this area targeting oncogenic receptor or oncogenic receptor (tyrosine) kinase in tumours [1-7]. The traditionally accepted view is that normal epidermal growth factor receptor (EGFR) is no tumorigenic [8].